How Investors and Lenders View This Niche

This is a capital-intensive niche before it is a revenue-generating one. Unlike a service business that can start with a laptop and a phone, a desalting and buffer-exchange venture needs processing equipment, a controlled environment, and a compliance record before a single biopharma client will sign a contract. That changes how you should approach the funding conversation: investors and lenders in this space are not asking "can you get customers," they are asking "can you get through validation and registration without running out of cash first."

The good news is that the entry barrier that scares off generalist competitors is exactly what protects you once you clear it. CDMOs have been increasing capital outlays for scalable buffer-exchange platforms since 2020, largely because smaller biotechnology firms are outsourcing more of their downstream processing rather than building it in-house. A plan that shows you understand this dynamic, and prices your equipment and compliance runway accordingly, reads very differently to a lender than a generic "we sell lab equipment" pitch.

Fill in the blanks with your own numbers once you have completed the startup-cost and revenue-model sections below, and this becomes the opening paragraph of your executive summary. Our Bespoke Business Plan service turns this into a full lender or investor-ready document, including the five-year forecast most SBA and UK Start Up Loan reviewers will ask for.

Two things separate a fundable plan from one that gets quietly filed away. First, specificity: an investor reading "we will provide bioprocessing services to the biotech sector" learns nothing, while one reading "we will run single-use TFF-based buffer-exchange batches for cell and gene therapy developers whose lot sizes fall below the 500L minimum most CDMOs require" immediately understands the wedge you are attacking. Second, sequencing: because certification and equipment procurement both take months, your funding ask should be phased, not a single lump sum. A typical structure raises enough to cover equipment deposit and ISO 13485 certification in the first tranche, then releases working capital once the quality system is in place and the first client contracts are signed, which reduces the investor's risk and usually improves your terms.

It also helps to be explicit about what kind of capital you are targeting. Angel investors and family offices active in the Golden Triangle life sciences corridor (London-Oxford-Cambridge) tend to understand equipment-heavy timelines already, whereas generalist seed funds may need the regulatory pathway explained in plain terms before they will commit. Grant programmes such as Innovate UK smart grants are also worth layering in alongside equity, since they are non-dilutive and specifically favour applied bioprocessing innovation rather than pure consumer-facing startups.

Market Size, Growth & Demand

Estimates vary by research house, which is normal for a specialised bioprocessing category, but they converge on the same direction. Precedence Research values the global desalting and buffer-exchange market at $1.25 billion in 2025, projecting growth to $2.99 billion by 2035 at a 9.10% compound annual growth rate. Fortune Business Insights puts the 2025 figure slightly lower at $1.14 billion, which is the kind of spread you should expect to see and should be comfortable explaining in a business plan rather than picking whichever number looks best.

Regionally, Mordor Intelligence reports North America holding a 37.8% revenue share in 2025, driven by the concentration of biopharmaceutical manufacturers, CDMOs, and research institutes across the US biotech corridors. Asia-Pacific is the fastest-growing region as biosimilar and vaccine manufacturing capacity expands, while Europe's share is anchored by clusters like Cambridge and the Stevenage Biomedical Campus in the UK.

A useful reality check for anyone drafting the market section of their plan: these figures describe the global market for the underlying products and services, not the addressable revenue available to a single new entrant. Your plan should translate the headline market size into a realistic serviceable segment, for example the number of small and mid-size biotech developers, CDMOs, and academic labs within your target geography that plausibly outsource buffer-exchange work, multiplied by a conservative estimate of how many of them you could realistically win as clients in year one. Lenders and investors have seen enough plans that simply restate the total global market size as if it were the founder's own opportunity, and they discount those plans heavily. A bottom-up estimate, built client by client, is far more persuasive than a top-down percentage of a multi-billion-dollar figure.

Demand is structural rather than cyclical: it tracks the biologics development pipeline, not consumer spending. Every monoclonal antibody, biosimilar, vaccine, or cell and gene therapy program needs desalting or buffer-exchange steps somewhere in downstream processing, and the growth of that pipeline is what is pulling the market forward. Established suppliers including Cytiva, Sartorius AG, Merck KGaA (MilliporeSigma), Repligen, Bio-Rad Laboratories, and Pall Corporation (part of Danaher) dominate the equipment and consumables side, while a newer wave of specialist CDMOs is competing on flexibility and turnaround for smaller clients those large suppliers are not built to serve quickly.

One concrete signal of where the big players are pointing their R&D budget: in July 2025, Cytiva launched the ÄKTA readyflux TFF system 500, an automated single-use tangential flow filtration platform specifically aimed at smaller-scale manufacturing runs. That is the same segment a new entrant should be targeting, since it confirms even the incumbents see unmet demand at the smaller batch sizes a lean new business can serve profitably before it has the capital for large-scale equipment.

It is worth spelling out, in plain terms, what this business actually does and why demand keeps climbing regardless of which individual biologic succeeds or fails in the clinic. Desalting removes salts and other low-molecular-weight contaminants from a biomolecule solution, typically leaving the target protein or nucleic acid suspended in water or a mild starting buffer. Buffer exchange takes that a step further, swapping the biomolecule into a specific new buffer chosen for the next stage of a process, whether that is an ion-exchange column, a formulation step, or an analytical assay. Almost every biologic, from a monoclonal antibody to an mRNA vaccine to a cell-therapy product, passes through one or more of these steps multiple times before it reaches a patient, and even small product losses at each step compound quickly when the underlying material is worth thousands of dollars per gram. That combination of high frequency and high value per touch is what makes the category resilient even when individual drug programmes are cancelled.

For a UK-based founder, the practical read is that demand is not confined to London and the South East. The Cambridge Biomedical Campus alone supports more than 22,000 jobs and co-locates the University of Cambridge with AstraZeneca, Abcam, and three NHS Trusts, while the Stevenage Biomedical Campus hosts GSK, the Cell & Gene Therapy Catapult Manufacturing Centre, and more than 45 resident start-ups that have collectively raised over £3.6 billion in equity, grants, and acquisitions since 2012. A new desalting and buffer-exchange business does not need to compete for space in central London; it needs to be close to one of these clusters, where potential clients already exist within walking distance and lab space is purpose-built for exactly this kind of operation.

Startup Costs & Funding Routes

Launching a desalting and buffer-exchange business typically requires $155,000 to $640,000 in the US, or £122,000 to £505,000 in the UK. The wide range reflects two very different starting points: a lean, service-only operation running contract buffer-exchange runs for a handful of clients sits at the lower end, while a fuller consumables manufacturing setup with in-house cleanroom production sits at the upper end.

Cost Breakdown

• Single-use TFF/UF-DF processing skid + desalting resin & spin-column inventory: $42,000–$165,000 (£33,000–£130,000)
• Cleanroom & lab buildout (ISO Class 8, biosafety cabinet, cold storage): $38,000–$150,000 (£30,000–£118,000)
• QC/analytical instrumentation (HPLC, conductivity/UV monitoring) + LIMS software: $25,000–$95,000 (£20,000–£75,000)
• ISO 13485 certification, FDA establishment registration, MHRA/UKCA registration: $15,000–$42,000 (£12,000–£33,000)
• Product/clinical liability insurance + facility insurance (annual): $8,000–$28,000 (£6,000–£22,000)
• Working capital (raw materials, staff, 6 months operating buffer): $27,000–$160,000 (£21,000–£127,000)

Each of these line items behaves differently as you scale, which matters when you are deciding where to spend your first funding tranche. The processing skid and resin inventory is the one true "must-have before revenue" cost, since no client will send a sample without confirming you can actually run it. Cleanroom buildout can often be phased, starting with a shared or serviced lab suite inside a bioscience campus rather than committing to a standalone facility on day one, which is exactly the approach taken in the case study further down this page. QC instrumentation can similarly start lean, with a basic UV-Vis spectrophotometer and conductivity meter covering your first client batches before you invest in HPLC or automated LIMS.

Regulatory costs are the line item founders most often underestimate, not because the fees themselves are large, but because certification timelines routinely run longer than expected. Budgeting six to twelve months between starting your ISO 13485 application and having a certificate in hand, rather than the three months many founders initially assume, is the single biggest factor separating plans that survive contact with reality from ones that run out of runway waiting on paperwork.

Funding Routes

In the US, SBA 7(a) loans cover up to $5 million with repayment terms up to 25 years for real estate and up to 10 years for equipment, and can be used to finance the processing skid and QC instrumentation directly. SBA 504 loans are also common for equipment-heavy laboratory and manufacturing startups because of their lower fixed-rate structure. Equipment financed this way must have a useful life beyond one year and serve a defined business function, which a TFF skid or desalting column line clearly meets.

In the UK, the Start Up Loans scheme offers up to £25,000 per founder (up to £100,000 for a founding team) at 6% fixed interest with free mentoring, though most founders in this niche will need to pair it with equity investment or an Innovate UK grant to reach the equipment budget described above. UK life-sciences founders based near clusters such as Stevenage Bioscience Catalyst or the Cambridge Biomedical Campus also benefit from proximity to angel networks already familiar with bioprocessing capital requirements, which can shorten the fundraising cycle considerably compared with pitching generalist investors cold.

Equipment leasing is worth serious consideration before committing to a purchase, particularly for the processing skid, which is the single largest capital item. Several single-use bioprocessing equipment manufacturers, including Cytiva and Sartorius, offer lease-to-own or pay-per-run financing structures for exactly this reason; smaller operators frequently cannot justify the full purchase price against uncertain first-year volume. A lease structure also reduces the amount you need to raise upfront, which in turn reduces dilution if you are funding primarily through equity rather than debt.

Whichever funding route you choose, lenders and investors alike will expect the plan to show a credible path to break-even, typically expressed in the number of client batches per month required to cover fixed costs. Founders who present this number with supporting logic, rather than a vague revenue growth curve, consistently get better reception from SBA loan officers and UK Start Up Loans delivery partners, both of whom see hundreds of generic plans a month and are trained to spot the ones that have genuinely modelled their own unit economics versus the ones that have copied a template.

Revenue Model, Pricing & Margins

Two revenue lines dominate this business: contract processing services and consumables sales. Contract buffer-exchange and diafiltration runs are typically billed $2,800 to $14,500 per batch, scaling with batch volume and complexity (bench-scale runs at the low end, pilot-scale at the high end). Consumables such as desalting cartridges and spin columns wholesale at $85 to $450 per unit depending on format and order volume.

Gross margins on contract processing services run 25% to 35%, consistent with published benchmarks for CDMO manufacturing services generally. When downstream-processing costs are passed through to a sponsor rather than billed as a flat fee, the typical markup applied is 15% to 25% over the underlying resin, membrane, and labour cost.

Worked example: a lean-launch buffer-exchange service running 10 client batches a month at a blended average price of $6,200 generates $744,000 in annual service revenue. At a 30% gross margin, consistent with the CDMO benchmarks above, that is roughly $223,000 in gross profit before overhead, staff salaries, and facility costs. This is why most first-year operators target 8-12 batches a month rather than immediately chasing the large-scale bioreactor runs that require far more capital and a different regulatory tier.

It is worth understanding why sponsors are willing to pay for this at all. Protein A resin, the standard capture step ahead of buffer exchange in monoclonal antibody manufacturing, costs roughly $10,000 to $15,000 per litre, and total downstream chromatography and filtration costs on a single 2,000-litre bioreactor batch producing a 2 g/L titre monoclonal antibody can reach $500,000. Against numbers like that, outsourcing the buffer-exchange step to a specialist who has already amortised the capital cost of the equipment is often cheaper for the sponsor than building the capability in-house, which is the core commercial argument your plan should make to both clients and investors.

Beyond per-batch processing fees and consumables sales, three secondary revenue streams are worth modelling explicitly in your plan even if they start small. Applications support and method development, charged as a day rate or fixed project fee, lets you monetise the process-development expertise most founders in this niche already have from prior roles, often before the main processing facility is even operational. Service contracts, where a client commits to a minimum monthly batch volume in exchange for a discounted per-batch rate and guaranteed slot availability, smooth out revenue variability and are attractive to lenders because they convert an otherwise lumpy sales pipeline into something closer to recurring revenue. Training and technology transfer fees, charged when a client eventually moves a validated process in-house or to a larger CDMO, can be a meaningful one-off revenue line and should be priced to reflect the real value of documentation and validation data rather than treated as an afterthought.

Seasonality is minimal in this business compared with consumer-facing sectors, but batch scheduling still needs to be modelled carefully. A single large client committing to eight batches in one month can crowd out three smaller clients who each wanted one or two, so most successful operators reserve a portion of monthly capacity for smaller, higher-margin one-off runs rather than filling the schedule entirely with a single anchor client, however tempting that client's volume may look on a spreadsheet.

Three Ways to Build This Business

Not every desalting and buffer-exchange business looks the same. Before writing your plan, decide which of these three models you are actually building, since the cost structure, regulatory burden, and sales cycle differ significantly between them.

Most first-time founders in this niche start with the contract-services model or the hybrid distributor model, because both avoid the largest capital outlay (a certified manufacturing line) while still generating real revenue within the first six to nine months. Consumables manufacturing is usually a second-stage move once a services or distribution business has built enough client relationships and cash flow to justify the larger buildout.

The choice also affects who you are competing against on day one. Contract services put you in a lane where large CDMOs simply do not compete for small batch sizes, so your realistic competitive set is other small specialist providers, not Cytiva or Sartorius directly. Consumables manufacturing puts you in direct competition with those established suppliers on their own turf, which is winnable but requires a genuinely differentiated product, not just a cheaper one. The hybrid distributor model sidesteps both fights by monetising expertise and relationships rather than owned equipment, at the cost of thinner control over service quality since you are reselling someone else's manufacturing output.

Whichever model you choose, write your business plan around that specific choice rather than describing all three. Investors and lenders read hedged, "we might do any of these" plans as a sign the founder has not yet made the hard decisions, whereas a plan that commits to one model with a clear rationale for why it is the right first move signals exactly the kind of judgment they are trying to underwrite.

Regulatory & Compliance Requirements

United States

• FDA Medical Device Establishment Registration: annual fee of $11,423 for FY2026 (up from $9,280 in FY2025), renewed every October–December
• ISO 13485 Quality Management System certification via an accredited body such as BSI or TÜV SÜD, typically $15,000–$35,000 including audits, 6–12 months to certify
• 21 CFR Part 820 Quality System Regulation compliance, built into your QMS from day one
• Material compatibility and leachables/extractables documentation for any single-use assemblies, which sponsor QA teams will request before placing a GMP order

United Kingdom

• Register your device/establishment with the MHRA (Medicines and Healthcare products Regulatory Agency): typically £3,000–£10,000 in consultancy and legal support to prepare the registration correctly
• UKCA marking under UK MDR 2002: became mandatory for the Great Britain market from July 2025, costing £8,000–£25,000 depending on device classification; CE marking is still recognised by the MHRA during the transition period, through 2028–2030 depending on device type
• ISO 13485 certification, generally accepted as evidence of an appropriate quality management system for UK conformity assessment

European Union

Selling into EU biopharma and CDMO customers alongside the UK market requires CE marking under EU MDR 2017/745, assessed through a Notified Body. Founders planning to serve both UK and EU clients from the outset should budget for both UKCA and CE processes in parallel rather than sequentially, since running them together is materially cheaper than doing one after the other.

Waste, Environmental & Facility Compliance

Beyond device and quality-system registration, most desalting and buffer-exchange operations also need to plan for biological and chemical waste handling from day one, since spent resin, used buffers, and single-use plastic assemblies all require documented disposal procedures. In the US this typically means a registered biohazard waste contractor and compliance with state-level Clinical Laboratory Improvement Amendments (CLIA) requirements if you handle any diagnostic samples; in the UK it means registering as a waste producer with the Environment Agency and holding appropriate consignment note records. Neither requirement is expensive on its own, generally a few thousand dollars or pounds a year in contractor fees, but both are the kind of item a first-time founder can genuinely forget to budget for, and a lender reviewing your plan will notice if it is missing.

It is also worth building a realistic compliance timeline into the plan rather than a single certification date. A typical sequence runs: quality management system documentation (months 1-3), facility and equipment installation qualification (months 3-6), ISO 13485 certification audit (months 6-9), FDA establishment registration and MHRA/UKCA filing in parallel (months 6-8), and first client validation runs (months 9-12). Presenting this as a Gantt-style timeline in your plan, rather than a single "we will be certified by month 6" line, is one of the simplest ways to show a lender or investor you understand the operational reality of this niche.

Common Mistakes to Avoid

• Under-costing the consumables burn rate. Resin, membranes, and single-use assemblies are consumed on every batch. New operators frequently run out of working capital before reaching the batch volume needed to break even, because the plan only budgeted for equipment, not ongoing consumable spend.
• Delaying ISO 13485 / FDA registration until after signing a first client. Biopharma QA teams will not place a GMP order with an unregistered, uncertified supplier, so starting the certification process late can stall a signed contract for months.
• Positioning as a generic "lab services" provider. Trying to compete broadly against Cytiva, Sartorius, and Repligen on their own terms is a losing fight for a new entrant. Specialising in one technique for one client segment, such as TFF-based buffer exchange for cell and gene therapy developers, is far easier to sell and to fund.
• Pricing contract runs per hour instead of per batch. Hourly pricing rarely captures the true cost of resin, membrane wear, and QC overhead, and erodes margin as batch complexity increases.
• Skipping leachables/extractables documentation for single-use assemblies. This is one of the first things a sponsor's quality team will ask for, and preparing it after the fact costs more time and money than building it into your process from the start.
• Underestimating the sales cycle for biopharma clients. Even a small biotech developer typically runs its own supplier qualification process before sending a paid sample, which can take eight to twelve weeks from first conversation to signed purchase order. Plans that assume revenue starts flowing within a month of opening the doors routinely run into cash-flow trouble before the first real contract lands.
• Treating the first client relationship as a one-off transaction rather than a reference. In a niche this specialised, word of mouth between process-development teams travels fast. Founders who under-deliver on their first client's timeline or documentation quality often find that reputation follows them into every subsequent pitch, while those who over-deliver gain referrals that materially shorten the sales cycle for every client after the first.

Sample Business Plan Preview

Here's an extract from a business plan written for a founder in this niche, so you can see exactly what you'll get:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your business at a glance, written to hook investors in 60 seconds
• Company Overview — Legal structure, ownership, location, and founding story
• Industry Analysis — Market size, growth trends, and the regulatory environment
• Target Market & Customer Analysis — Buyer segments, decision triggers, and spending patterns specific to biopharma and CDMO procurement
• Competitor Analysis — Mapping incumbent suppliers and the gaps a new entrant can realistically win
• Operations Plan — Equipment, facility, staffing, and batch workflow
• Regulatory & Compliance Plan — FDA, MHRA, ISO 13485, and quality system milestones on a realistic timeline
• Management Team — Founder bios, advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements, built to withstand SBA or UK lender scrutiny.

If you are still deciding whether this is the right niche, our Market Research & Content package can validate the customer segment and regulatory pathway before you commit capital to equipment. Founders exploring adjacent niches may also find our laboratory equipment manufacturer and biotechnology reagents business plan templates useful for comparison, and our general business plan writer service if you want a consultant involved from the first draft rather than joining partway through.

Every template is written to stand on its own, but the sections that carry the most weight with lenders and investors in a capital-intensive, regulated niche like this one are the operations plan and the regulatory and compliance plan. Generic business plan software rarely handles either well, since both require industry-specific knowledge of equipment lead times, certification sequencing, and the specific vocabulary a biopharma or CDMO buyer expects to see. That is the gap our industry-specific templates and bespoke writing service are built to close.

Frequently Asked Questions